Logo
x

Search category

Subscribe Now

The US FDA

Gilead's Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) Low-Dose Tablet Receives the US FDA's Approval for Expanded Indication to Treat HIV-1

Gilead's Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) Low-Dose Tablet Receives the US FDA's Approval for Expanded In...

  • October 19, 2021
Genentech's Tecentriq Receives the US FDA's Approval as Adjuvant Treatment for Early Non-Small Cell Lung Cancer

Genentech's Tecentriq Receives the US FDA's Approval as Adjuvant Treatment for Early Non-Small Cell Lung Cancer

  • October 18, 2021
Boehringer Ingelheim's Cyltezo (biosimilar- adalimumab) Receives the US FDA's sBLA Approval as the 1st Interchangeable Biosimilar for Multiple Chronic Inflammatory Diseases

Boehringer Ingelheim's Cyltezo (biosimilar- adalimumab) Receives the US FDA's sBLA Approval as the 1st Interchangeable Biosimilar...

  • October 18, 2021
Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following the US FDA's Acceptance of IND for P-I Study of XL114 in Non-Hodgkin's Lymphoma

Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following the US FDA's Acceptance of IND for P-I Study of XL114 in...

  • October 15, 2021
PharmaTher's Ketamine Receives the US FDA's Orphan Drug Designation for Complex Regional Pain Syndrome

PharmaTher's Ketamine Receives the US FDA's Orphan Drug Designation for Complex Regional Pain Syndrome

  • October 14, 2021
Merck's Keytruda (pembrolizumab) Receives the US FDA's Approval for Second Indication in Cervical Cancer

Merck's Keytruda (pembrolizumab) Receives the US FDA's Approval for Second Indication in Cervical Cancer

  • October 14, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.